A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

Last updated:
2026-07-18
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND PROGRAM TO EVALUATE EFFICACY AND SAFETY OF UPADACITINIB IN ADULT AND ADOLESCENT SUBJECTS WITH SEVERE ALOPECIA AREATA

Intervention/treatment:
UPADACITINIB (ABT-494)
Medical condition:
ALOPECIA AREATA
Protocol code:
M23-716
Control number:
278435
Status:
Recruiting
Approved:
November 06, 2023
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT06012240
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
12 Years to 63 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
ABBVIE CALL CENTER
Role
CONTACT
Phone:
844-663-3742
Sponsor
ABBVIE CORPORATION

Locations

Alberta

Beacon Dermatology /ID# 258817
Calgary, Alberta, T3A 2N1
Active, not recruiting
Dermatology Research Institute - Blackfoot Trail /ID# 258818
Calgary, Alberta, T2J 7E1
Active, not recruiting
Rejuvenation Dermatology - Edmonton Downtown /ID# 258816
Edmonton, Alberta, T5J 3S9
Active, not recruiting

British Columbia

Dr. Chih-ho Hong Medical Inc. /ID# 258814
Surrey, British Columbia, V3R 6A7
Active, not recruiting

Manitoba

Wiseman Dermatology Research /ID# 258819
Winnipeg, Manitoba, R3M 3Z4
Active, not recruiting

Ontario

JRB Research /ID# 259248
Ottawa, Ontario, K1H 7X3
Active, not recruiting
Leader Research /ID# 267028
Hamilton, Ontario, L8L 3C3
Active, not recruiting
Lynderm Research Inc /ID# 258815
Markham, Ontario, L3P 1X2
Active, not recruiting
Medicor Research Inc /ID# 258810
Greater Sudbury, Ontario, P3C 1X3
Active, not recruiting
Private Practice - Dr. Kim Papp Clinical Research /ID# 259249
Waterloo, Ontario, N2J 1C4
Active, not recruiting
SimcoDerm Medical and Surgical Dermatology Center /ID# 258820
Barrie, Ontario, L4M 7G1
Active, not recruiting
SKiN Centre for Dermatology /ID# 258813
Peterborough, Ontario, K9J 5K2
Active, not recruiting
York Dermatology Clinic and Research Centre /ID# 267026
Richmond Hill, Ontario, L4C 9M7
Active, not recruiting

Quebec

Centre de Recherche dermatologique du Quebec Metropolitain /ID# 258811
Québec, Quebec, G1V 4X7
Active, not recruiting
Innovaderm Research Inc. /ID# 258812
Montreal, Quebec, H2X 2V1
Active, not recruiting
Private Practice - Dr. Angelique Gagne-Henley /ID# 267027
Saint-Jérôme, Quebec, J7Z 7E2
Active, not recruiting
Did you find what you were looking for?

Contacts and resources